Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic
· smallcaps.com.au
Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.
The US Food and Drug Adminstration has granted Clarity Pharmaceuticals (ASX: CU6) breakthrough therapy designation for 64Cu-SAR-bisPSMA used in positron emissio...